Sodium-glucose Cotransporter 2 Inhibitors: Nephroprotective Impact on Diabetic Kidney Disease

Abstract

The initial data suggest clinically meaningful benefits of the SGLT-2 inhibitors in diabetic patients in relevance with chronic kidney disease. Future, well-designed randomised clinical trials need to be further investigated such as nephroprotective outcomes, that if confirmed, could lead to new perspectives in the management of diabetic nephropathy.

Editorial: Receptor Biology and Cell Signaling in Diabetes

“…Recently, many renal protective agents that modulate the receptor physiology and improve cellular health and homeostasis, including sodium-glucose cotransporter inhibitors (SGLT-2), DPP-4 inhibitors, and N-seryl-acetyl-lysyl-proline, have been evaluated in preclinical settings and some in controlled clinical trials with promising outcomes ( Kanasaki et al, 2014 ; Srivastava et al, 2016 ; Stavropoulos et al, 2018 ; Srivastava et al, 2020a ; Srivastava et al, 2020b ). Moreover, larger sample size is necessary to optimize their use in human beings.…”

Editorial: Combating Diabetes and Diabetic Kidney Disease

“…Moreover, these therapies are neither tissue- nor cell-specific and are ineffective in reversing kidney fibrosis and diabetic complications. In recent years, a number of reno-protective agents, including sodium glucose co-transporter (SGLT-2) inhibitors, mineralocorticoid receptor antagonists, endothelin A antagonists, dipeptidyl transferse-4 (DPP-4) inhibitors, and N-seryl-acetyl-lysyl-proline have been studied in both preclinical settings and in controlled clinical trials, some with promising outcomes ( Kanasaki et al, 2014 ; Stavropoulos et al, 2018 ; Srivastava et al, 2020b ). Still, more research is needed to validate their cell- and tissue-specific mechanisms to optimize their use in human disease.…”